- Datum26.02.2026
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Kymera Therapeutics Inc. Registered Shares DL -,0001 Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Kymera Therapeutics Inc. Registered Shares DL -,0001 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Société Générale | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,95 %
Intraday
2,93 %
1 Woche
6,33 %
1 Monat
2,17 %
Seit Jahresbeginn
120,59 %
1 Jahr
139,46 %
3 Jahre
16,71 %
5 Jahre
Passender Service zu Kymera Therapeutics Inc. Registered Shares DL -,0001
Webinar zu Kymera Therapeutics Inc. Registered Shares DL -,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)19,445-103,000
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Kymera Therapeutics Inc. Registered Shares DL -,0001
Keine Dividenden verfügbar
Termine von Kymera Therapeutics Inc. Registered Shares DL -,0001
- Feb19Kymera Therapeutics Inc. Registered Shares DL -,0001Q4 2025 Earnings Release
- Apr30Kymera Therapeutics Inc. Registered Shares DL -,0001Q1 2026 Earnings Release
- Jul31Kymera Therapeutics Inc. Registered Shares DL -,0001Q2 2026 Earnings Release
Beschreibung
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
